Abstract
Introduction
This Datamonitor study examines top business challenges, IT budget outlook,
and spending priorities among pharmaceutical and biotechnology companies in
the US, the UK, France, Germany, and India. It is based on the results of
Datamonitor' s Business Trends primary research, conducted in Q3 and Q4 2007,
with a total of 150 life science companies.
Scope
In-depth interviews with 150 pharmaceutical and biotechnology companies
Geographic coverage includes: the US, the UK, France, Germany, and India The
study focuses on the business challenges, IT budget outlook, and the degree to
which the market has adopted EDC and SOA solutions Respondents included IT
decision-makers such as CIOs and CTOs
Highlights
IT vendors targeting the life science market must demonstrate deep industry
knowledge and have high expertise in their specialty product. Companies in the
life science industry must build and maintain their product pipeline to
compete with generic drug manufacturers. To achieve this, companies are
beginning to change their business models, albeit slow, and are investing more
money into technology solutions. Pharmaceutical and biotechnology companies
have several goals that affect their IT strategies, including achieving or
maintaining regulatory compliance, raising efficiency, and aligning IT with
overall business objectives.
Reasons to Purchase
Validate your market messaging and positioning in the life science industry
Compare pharmaceutical and biotechnology IT purchasing plans across
geographies Identify emerging areas of concern for pharmaceutical and
biotechnology companies.
View Cart
